Immunotherapy in NSCLC Patients with Brain Metastases

被引：21

作者：

Buriolla, Silvia ^{[1
]}

Pelizzari, Giacomo ^{[2
]}

Corvaja, Carla ^{[1
]}

Alberti, Martina ^{[1
]}

Targato, Giada ^{[1
]}

Bortolot, Martina ^{[1
]}

Torresan, Sara ^{[1
]}

Cortiula, Francesco ^{[2
]}

Fasola, Gianpiero ^{[2
]}

Follador, Alessandro ^{[2
]}

机构：

[1] Univ Udine, Dept Med DAME, I-33100 Udine, Italy

[2] Azienda Sanitaria Univ Friuli Cent ASUFC, Dept Oncol, I-33100 Udine, Italy

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2022年 / 23卷 / 13期

关键词：

NSCLC; immunotherapy; brain; metastases; CELL LUNG-CANCER; NIVOLUMAB PLUS IPILIMUMAB; OPEN-LABEL; 1ST-LINE TREATMENT; POOLED ANALYSIS; ITALIAN COHORT; PEMBROLIZUMAB; CHEMOTHERAPY; BLOCKADE; MELANOMA;

D O I：

10.3390/ijms23137068

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Approximately 40% of unselected non-small cell lung cancer (NSCLC) patients develop brain metastases (BMs) during their disease, with considerable morbidity and mortality. The management of BMs in patients with NSCLC is a clinical challenge and requires a multidisciplinary approach to gain effective intracranial disease control. Over the last decade, immune checkpoint inhibitors (ICIs) have emerged as a game-changer in the treatment landscape of advanced NSCLC, with significant improvements in survival outcomes, although patients with BMs are mostly underrepresented in randomized clinical trials. Moreover, the safety and activity of ICIs and radiotherapy combinations compared with single-agent or sequential modalities is still under evaluation to establish the optimal management of these patients. The aim of this review is to summarize the state-of-the-art of clinical evidence of ICIs intracranial activity and the main challenges of incorporating these agents in the treatment armamentarium of NSCLC patients with BMs.

引用

页数：12

共 76 条

[1] Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation [J].

Allen, Elizabeth ;

Jabouille, Arnaud ;

Rivera, Lee B. ;

Lodewijckx, Inge ;

Missiaen, Rindert ;

Steri, Veronica ;

Feyen, Kevin ;

Tawney, Jaime ;

Hanahan, Douglas ;

Michael, Iacovos P. ;

Bergers, Gabriele .

SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (385)

[2] Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy [J].

Althammer, Sonja ;

Tan, Tze Heng ;

Spitzmuller, Andreas ;

Rognoni, Lorenz ;

Wiestler, Tobias ;

Herz, Thomas ;

Widmaier, Moritz ;

Rebelatto, Marlon C. ;

Kaplon, Helene ;

Damotte, Diane ;

Alifano, Marco ;

Hammond, Scott A. ;

Dieu-Nosjean, Marie-Caroline ;

Ranade, Koustubh ;

Schmidt, Guenter ;

Higgs, Brandon W. ;

Steele, Keith E. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7

[3] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[4] Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer [J].

Arbour, Kathryn C. ;

Mezquita, Laura ;

Long, Niamh ;

Rizvi, Hira ;

Auclin, Edouard ;

Ni, Andy ;

Martinez-Bernal, Gala ;

Ferrara, Roberto ;

Lai, W. Victoria ;

Hendriks, Lizza E. L. ;

Sabari, Joshua K. ;

Caramella, Caroline ;

Plodkowski, Andrew J. ;

Halpenny, Darragh ;

Chaft, Jamie E. ;

Planchard, David ;

Riely, Gregory J. ;

Besse, Benjamin ;

Hellmann, Matthew D. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) :2872-+

[5] Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study) [J].

Assie, Jean-Baptiste ;

Corre, Romain ;

Levra, Matteo Giaj ;

Calvet, Christophe Yannick ;

Gaudin, Anne-Francoise ;

Grumberg, Valentine ;

Jouaneton, Baptiste ;

Cotte, Francois-Emery ;

Chouaid, Christos .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12

[6] CheckMate 817: First-Line Nivolumab plus Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC [J].

Barlesi, F. ;

Audigier-Valette, C. ;

Felip, E. ;

Ciuleanu, T. ;

Jao, K. ;

Rijavec, E. ;

Urban, L. ;

Aucoin, J. ;

Zannori, C. ;

Vermaelen, K. ;

Frontera, O. A. ;

Ready, N. ;

Fontecedro, A. Curioni ;

Linardou, H. ;

Poddubskaya, E. ;

Fischer, J. ;

Iordan, I. ;

Groen, H. ;

Pillai, R. ;

Li, S. ;

Fiore, J. ;

Chang, H. ;

Acevedo, A. ;

Paz-Ares, L. .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) :S214-S215

[7] Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers [J].

Berghoff, Anna S. ;

Schur, Sophie ;

Fuereder, Lisa M. ;

Gatterbauer, Brigitte ;

Dieckmann, Karin ;

Widhalm, Georg ;

Hainfellner, Johannes ;

Zielinski, Christoph C. ;

Birner, Peter ;

Bartsch, Rupert ;

Preusser, Matthias .

ESMO OPEN, 2016, 1 (02)

[8]

Bidoli P., 2016, ANN ONCOL, P27, DOI [10.1093/annonc/mdw383.28, DOI 10.1093/ANNONC/MDW383.28]

[9]

Borghaei H., 2020, Cancer Res, V80, pCT221, DOI [10.1158/1538-7445.AM2020-CT221, DOI 10.1158/1538-7445.AM2020-CT221]

[10]

Borghaei H, 2021, J CLIN ONCOL, V39, P723, DOI 10.1200/JCO.20.01605

← 1 2 3 4 5 6 7 8 →